
The CEO Of Novo Claims That the Obesity Industry Won’t Be a Winner-Take-All Contest with Lilly
The CEO Of Novo Claims That the Obesity Industry Won’t Be a Winner-Take-All Contest with Lilly Investors are underestimating the need for differentiation among obesity medications, according to CEO Mike Doustdar of Novo Nordisk (NOVOb.CO), and novel treatment choices such pills will prevent it from becoming a winner-take-all struggle with rival Eli Lilly. In a sector that some predict could





















